Your browser doesn't support javascript.
loading
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
Fabian, Kellsye P; Padget, Michelle R; Fujii, Rika; Schlom, Jeffrey; Hodge, James W.
Affiliation
  • Fabian KP; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Padget MR; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Fujii R; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Schlom J; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Hodge JW; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA jh241d@nih.gov.
J Immunother Cancer ; 9(2)2021 02.
Article in En | MEDLINE | ID: mdl-33602696

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Colorectal Neoplasms / Vaccines, DNA / Triple Negative Breast Neoplasms / Antineoplastic Agents, Immunological / Docetaxel / Immune Checkpoint Inhibitors Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Colorectal Neoplasms / Vaccines, DNA / Triple Negative Breast Neoplasms / Antineoplastic Agents, Immunological / Docetaxel / Immune Checkpoint Inhibitors Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: Country of publication: